<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00280696</url>
  </required_header>
  <id_info>
    <org_study_id>N01221</org_study_id>
    <secondary_id>2014-004333-57</secondary_id>
    <nct_id>NCT00280696</nct_id>
  </id_info>
  <brief_title>A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam Used as add-on Therapy at Doses of 0.5 to 3 g/Day in Patients From 16 to 65 Years With Epilepsy With Partial Onset Seizures Under Treatment With 1 to 3 Anti-epileptic Drug(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Japan Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, multicenter, placebo controlled 5 parallel groups, confirmatory
      trial to evaluated the efficacy and safety of levetiracetam used as adjunctive treatment in
      patients from 16 to 65 years with epilepsy suffering from partial onset seizures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction from Baseline in partial (Type I) seizure frequency per week over the Evaluation Period</measure>
    <time_frame>From Baseline to the 12-week Evaluation Period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial (Type I) seizure frequency per week over the Evaluation Period</measure>
    <time_frame>12-week Evaluation Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial (Type I) seizure responder rates (50 %, 75 %) over the Evaluation Period</measure>
    <time_frame>From Baseline to the 12-week Evaluation Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure freedom over the Evaluation Period</measure>
    <time_frame>12-week Evaluation Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorized percentage reduction from Baseline in partial (Type I) seizure frequency per week over the Evaluation Period</measure>
    <time_frame>From Baseline to the 12-week Evaluation Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction from Baseline in seizure frequency per week by seizure subtype (IA, IB, IC, IA + IB, other) over the Evaluation Period</measure>
    <time_frame>From Baseline to the 12-week Evaluation Period</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Epilepsies, Partial</condition>
  <arm_group>
    <arm_group_label>Lev 0.5 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lev 1 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lev 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lev 3 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam 250 mg</intervention_name>
    <description>Active Substance: Levetiracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 250 mg
Route of Administration: Oral Use</description>
    <arm_group_label>Lev 0.5 g</arm_group_label>
    <arm_group_label>Lev 1 g</arm_group_label>
    <arm_group_label>Lev 2 g</arm_group_label>
    <arm_group_label>Lev 3 g</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam 500 mg</intervention_name>
    <description>Active Substance: Levetiracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 500 mg
Route of Administration: Oral Use</description>
    <arm_group_label>Lev 1 g</arm_group_label>
    <arm_group_label>Lev 2 g</arm_group_label>
    <arm_group_label>Lev 3 g</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Active Substance: Placebo
Pharmaceutical Form: Film-coated tablet
Concentration: 250 mg and 500 mg
Route of Administration: Oral Use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Epileptic patients who fulfill the following criteria are eligible for inclusion in the
        study:

          -  Subjects aged from 16 to 65 years at the acquisition of informed consent to the trial
             participation

          -  Seizure type: subjects with epileptic seizures which were diagnosed as partial
             seizures more than 2 years ago according to &quot;Clinical and electroencephalographic
             classification of epileptic seizures (1981)&quot; defined by the International League
             Against Epilepsy (ILAE) and confirmed with an EEG that has been performed within 1
             year before Screening or at the Screening Visit

          -  Subjects whose previous therapy before screening involved at least two standard
             anti-epileptic drugs (AEDs) for partial seizures, and in whom it can be confirmed that
             the doses met the daily dose specified for the treatment of epilepsy in the package
             insert and that the therapy has been continued for at least 3 months

          -  Frequency of epileptic seizures: subjects experiencing partial seizures at least 12
             times in 12 weeks during the Baseline Period (Week âˆ’12 to Week 0) and at least twice
             in every 4 weeks

        Exclusion Criteria:

        The following patients are not eligible for inclusion into the study:

          -  Subjects who were diagnosed with status epilepticus within 3 months before screening

          -  Subjects with no partial seizures of which frequency was measured during the Baseline
             Period

          -  Subjects who underwent surgery for epilepsy within 2 years before Screening or who
             were scheduled to undergo brain surgery during the study period and within 4 weeks
             after the completion of this study

          -  Subjects with a history of oral treatment with Levetiracetam (LEV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aichi-gun</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nayoga</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyusyu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hakodate</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kahoku-gun</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kikuchi-gun</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neyagawa</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawachi-gun</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gihu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagaoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/N01221_CSS_20081117.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2006</study_first_submitted>
  <study_first_submitted_qc>January 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2006</study_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsies, Partial,</keyword>
  <keyword>Keppra, levetiracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

